New Ray Medicine International Holding Limited reported 1H26 revenue of HK$113.42 million, up 153.7% from HK$44.70 million a year earlier, driven chiefly by stronger sales of chemical reagents and injection drugs.

Net loss attributable to shareholders narrowed 52.2% to HK$3.57 million (1H25: HK$7.45 million) as gross profit rose to HK$9.84 million from HK$3.64 million. Gross margin improved to 8.68%, versus 8.13% in the prior-year period.

Segment Performance • Distribution and trading of pharmaceutical and related products generated HK$112.61 million, accounting for 99.3% of total revenue and growing 161.5% year on year. • Marketing and promotion services contributed HK$0.81 million, down 50.7%.

Operating Metrics • Selling and distribution expenses increased 27.0% to HK$6.32 million, while administrative expenses rose 14.2% to HK$6.85 million. • Other income, gains and losses recorded a HK$1.55 million net loss, chiefly reflecting a HK$1.73 million exchange loss. • Fair value gains on financial assets at FVTPL totalled HK$2.10 million (1H25: HK$0.68 million).

Financial Position • Cash and cash equivalents stood at HK$73.58 million (31 Dec 2025: HK$29.42 million). • Total assets were HK$471.08 million with no borrowings, leaving the gearing ratio at zero. • Equity attributable to shareholders increased to HK$435.85 million from HK$424.22 million at year-end.

Dividend The Board declared no interim dividend (1H25: nil).

Outlook Management highlighted ongoing industry pressure from China’s volume-based procurement programme but intends to diversify the product portfolio, expand sales channels and concentrate resources on core pharmaceutical distribution and marketing operations.

No material contingent liabilities, pledges of assets, or post-period events were reported.